Trials / Unknown
UnknownNCT02005757
Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)
Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.
Detailed description
1. EULAR Response after 24weeks of treatment 2. EULAR Response after 12weeks of treatment 3. DAS28 value change 4. KHAQ-20 value change
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bredinin tablet 150mg | Bredinin 150mg qd vs Bredinin 50mg tid |
| DRUG | Bredinin tablet 50mg | Bredinin 150mg qd vs Bredinin 50mg tid |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-06-01
- Completion
- 2016-10-01
- First posted
- 2013-12-09
- Last updated
- 2015-06-26
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02005757. Inclusion in this directory is not an endorsement.